Prevalence of Antiphospholipids Antibodies in Pregnant Women seen in Prenatal Consultation in a Public Maternity of Niamey, Niger
 |
International Journal of Biotech Trends and Technology (IJBTT) | 
|
| © 2015 by IJBTT Journal | ||
| Volume-12 |
||
| Year of Publication : 2015 | ||
| Authors : Boutchi M, Aridouane DD, Garba M, Akpona SA |
Citation
Boutchi M, Aridouane DD, Garba M, Akpona SA "Prevalence of Antiphospholipids Antibodies in Pregnant Women seen in Prenatal Consultation in a Public Maternity of Niamey, Niger", International Journal of Biotech Trends and Technology (IJBTT),V12:7-10 September-October 2015. Published by Seventh Sense Research Group.
Abstract
The antiphospholipids antibodies lupus like are oriented against the membraneous phospholipids and can be associated to serious complications of pregnancy. The objective of this survey was to determine the prevalence of this type of antibody in pregnant women that come for prenatal consultation to Issaka Gazobi maternity of Niamey. The selection of the sample was done on the basis of clinical information on pregnancy complication evoking the syndrome of antiphospholipids antibodies. In presence of an antiphospholipid antibody, the activated partial thromboplastin time (APTT) of the patient is lengthened. APTT on the mixture of the plasma of the patient to equal part of the plasma of control also remains stretched out because of the inhibitory effect of the antibody. During the period of the survey 1960 pregnant women have been consulted among which 35 have been suspected of the antibodies antiphospholipids syndrome, weither a rate of 1,83%. The main motives of consultations were the threats of miscarriages (40, 35%) and pre-eclampsy (26,42%). The antiphospholipids antibodies of lupus type has been detected in 37,14% of cases and in 25,71% it has been underlined. The aspirin alone-based treatment has lead 88,90% of pregnancies at term. These results showed up a high prevalence of anticoagulants circulating lupus in the pregnant in Niamey. The use of aspirin 100 mgs per day permitted to avoid obstetric complications.
References
[1] Kwak-Kim J, Agcaoili MSL, Aleta L, Liao A, Ota K, Dambaeva S, Beaman K, Kim JW, Gilman-Sachs A. Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome. Am J Reprod Immunol 2013; 69: 596–607.
[2] WANG Yong-qing, NIU Ji-hong, WANG Jia-lue, YE Ronghua and ZHAO Yang-yu. Patient with antiphospholipid syndrome accompanied by pre-eclampsia who developed hellp syndrome and eclampsia after abortion. Chin Med J 2012; 125(22):4142-4144 [3] Levine JS, branch DW, Rauch J. The antiphospholipid syndrome.
N Engl J Med 2002; 346:752-63 [4] Diariétou D A. Retard de croissance intra utérine a la maternité Issaka Gazobi de Niamey. Etude prospective a propos de 183 cas.Thèse de médecine ; FSS de Niamey ; 2009 n°1665.
[5] Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185–90.
[6] Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detectionand quantitative evaluation of lupus circulating anticoagulantactivity. Thromb Haemost 1987; 57: 144-7.
[7] Amel AA AL Samarrai, Ferial A Hilmi, Nasir AS Al-Allawi, and Amal F Murad. Antiphospholipid Antibodies in Iraqi Women with Recurrent Mid-Trimester Abortions. J Lab Physicians. 2012 Jul-Dec; 4(2): 78
[8] Cambon-EsztoM-L. Etude de la cinétique des anticorps anticardiolipides dans les grossesses à risque. Thèse de Medecine.Faculté de Médecine de Nancy ; 2004 ; n°87.
[9] Heilmann L, Schorch M, Hahn T, Adasz G, Schilberz K, Adiguzel C, and Fareed J. Pregnancy Outcome in Women with Antiphospholipid Antibodies: Report on a Retrospective Study. Seminars in Thrombosis and Hemostasis/Volume 34, Number 8; 2008
[10] Institut National de la Statistique (INS) et ICF international, 2013. Enquête démographique et de santé et à indicateurs multiples du Niger 2012. Calverton, Maryland, USA : INS et ICF International
[11] Bentolila S, Bellucci S, Drouet L. Anticorps antiphospholipide et grossesse. http://pro.gyneweb.fr/portail/sources/congres/jta/98/divers/ac phospholip.html. Consulté le 28/10/2014
[12] Carreras LO, Vermylen J, Spitz B, Van Assche A. "Lupus" anticoagulant and inhibition of prostacyclin formation in patients with repeated abortion,intrauterine growth retardation and intrauterine death. Br J ObstetGynaecol. 1981 Sep;88(9):890-4
[13] Derksen RH1, Hasselaar P, Blokzijl L, GmeligMeyling FH, De Groot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis. 1988 May;47(5):364-71
[14] Jalloulia M, kaddoura N, Friguia M, et al. Le syndrome des antiphospholipidesa propos de 74 cas. Revue de médecine interne 27 (2006)
[15] Magy N, Gil H, Racadot EE, Dupond JL. Relative value of antiphospholipid antibodies detected in a department of internal medicine: retrospective study of 124 patients. Revue de médecine interne 23 (2002) 696–702
[16] Noble LS1, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. FertilSteril. 2005 Mar;83(3):684-90
[17] A Vashisht L Regan. Antiphospholipid syndrome in pregnancy – an update.J R Coll Physicians Edinb 2005; 35:337–339
[18] XiaoJ, Xiong J, Zhu F and He L. Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Experimental and therapeutic medicine 2013;5: 287-291,
[19] Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). MJ 1997; 314(7076):253–7.
Keywords
Antibody antiphospholipids, pregnancy, aspirin, Niamey.